Skip to main content
. 2014 Mar 13;55(3):153–160. doi: 10.4111/kju.2014.55.3.153

TABLE 1.

Key trials with new agents in nonmetastatic castration-resistant prostate cancer

graphic file with name kju-55-153-i001.jpg

BMFS, bone-metastasis-free survival; MFS, metastasis-free survival; CAB, combined androgen blockade; EGFR, epidermal growth factor receptor; NM-CRPC, nonmetastatic castration-resistant prostate cancer; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen; TTP, time to disease progression; VEGF, vascular endothelial growth factor.